Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part

被引：0

作者：

Cortes, J. ^{[1
,2
]}

Martinez Janesz, N. ^{[1
]}

Sablin, M. P. ^{[3
]}

Perez-Fidalgo, J. A. ^{[4
]}

Neven, P. ^{[5
]}

Hedayati, E. ^{[6
,7
]}

Ballester, A. ^{[8
]}

Ehrhart, M. P. ^{[9
,10
]}

Huang, D. Chin-Lun ^{[11
]}

Bogenrieder, T. ^{[12
]}

Schmid, P. ^{[13
]}

机构：

[1] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[2] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[3] Inst Curie, Dept Med Oncol, Paris, France

[4] Hosp Clin Univ Valencia, Dept Haematol & Med Oncol, Valencia, Spain

[5] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium

[6] Karolinska Inst, Stockholm, Sweden

[7] Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden

[8] Boehringer Ingelheim Espana SA, Dept Med Oncol, Barcelona, Spain

[9] Staburo GmbH, Munich, Germany

[10] Boehringer Ingelheim Pharma GmbH & Co KG, St Joseph, MO USA

[11] Boehringer Ingelheim Taiwan Ltd, Med, Taipei, Taiwan

[12] Boehringer Ingelheim RCV, Med, Vienna, Austria

[13] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England

来源：

EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

389

引用

页码：S112 / S112

页数：1

共 50 条

[31] A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)
Herold, Christina I.
Trippa, Lorenzo
Li, Tianyu
Khanh Do
Bardia, Aditya
Anderson, Leilani
Montazeri, Kamaneh
Pittenger, Jessica
Andrews, Chelsea
Mittendorf, Elizabeth A.
Goel, Shorn
Winer, Eric P.
Shapiro, Geoffrey I.
Tolaney, Sara M.
CANCER RESEARCH, 2020, 80 (04)
[32] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor trial
Dirix, L. Y.
Takacs, I.
Nikolinakos, P.
Jerusalem, G.
Arkenau, H-T
Hamilton, E. P.
von Heydebreck, A.
Grote, H-J
Chin, K.
Lippman, M. E.
CANCER RESEARCH, 2016, 76
[33] Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
Moy, Beverly
Neven, Patrick
Lebrun, Fabienne
Bellet, Meritxell
Xu, Binghe
Sarosiek, Tomasz
Chow, Louis
Goss, Paul
Zacharchuk, Charles
Leip, Eric
Turnbull, Kathleen
Bardy-Bouxin, Nathalie
Duvillie, Ladan
Lang, Istvan
ONCOLOGIST, 2014, 19 (04): : 348 - 349
[34] Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
Kornblum, Noah
Zhao, Fengmin
Manola, Judith
Klein, Paula
Ramaswamy, Bhuvaneswari
Brufsky, Adam
Stella, Phillip J.
Burnette, Brian
Telli, Melinda
Makower, Della F.
Cheema, Puneet
Truica, Cristina I.
Wolff, Antonio C.
Soori, Gamini S.
Haley, Barbara
Wassenaar, Timothy R.
Goldstein, Lori J.
Miller, Kathy D.
Sparano, Joseph A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1556 - +
[35] Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study
Zhang, Qingyuan
Wang, Jingxuan
Li, Liru
Zeng, Xiaohua
Zhang, Han
Song, Ying
Tang, Dabei
Niu, Xingjian
Ma, Wenjie
Tu, Lifan
Fu, Shuang
Pan, Zoucheng
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope S.
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara A.
Loibl, Sibylle
Kummel, Sherko
Scartoni, Simona
Matheny, Shannon
Theall, Kathy Puyana
O'shaughnessy, Joyce
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
[37] Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status
Wesolowski, Robert
Rugo, Hope
Stringer-Reasor, Erica
Han, Hyo S.
Specht, Jennifer M.
Dees, E. Claire
Kabos, Peter
Vaishampayan, Ulka
Wander, Seth A.
Lu, Janice
Gogineni, Keerthi
Spira, Alexander I.
Schott, Anne F.
Abu-Khalaf, Maysa
Nayak, Pratima
Sullivan, Brian F.
Gorbatchevsky, Igor
Layman, Rachel M.
CANCER RESEARCH, 2023, 83 (05)
[38] A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER plus ) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer.
Moyo, V. M.
Higgins, M. J.
Aravelo-Araujo, R.
Iannotti, N.
Charu, V.
Dhindsa, N.
Goss, P. E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[39] Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2-metastatic breast cancer (MBC)
Diamond, J.
Borges, V. F.
Kabos, P.
Krill-Jackson, E.
Graham, R.
Hoffman, A.
Lim, B.
Richards, D. A.
Salkeni, M. A.
Wilks, S.
Patel, C.
Neuwirth, R.
Kneissl, M.
Zohren, F.
ANNALS OF ONCOLOGY, 2016, 27
[40] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
Borges, Virginia F.
Chan, Arlene
Lin, Nancy U.
Tonda, Margaret Eleanor
Shilkrut, Mark
Alemany, Carlos A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →